PARP1 and glioblastoma: To further unmask the effect of FA consumption in the resistance to PARP inhibitors, we treated GBM cells with the β-oxidation inhibitor Etomoxir, which potentiated PJ34-induced cell death analyzed as SubG1 fraction (Figure 5B).